ObvioHealth
ObvioHealth sells ObvioGo, a unified no-code decentralized clinical trial platform that consolidates eConsent, ePRO/eCOA, virtual visits, and device integration into a single system for pharma, biotech, CROs, medical device, and consumer health sponsors globally.
- Company typePrivate
- Founded2017
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What ObvioHealth does
ObvioHealth is a privately held digital clinical trials company founded in 2017 and headquartered in New York, with a Singapore parent entity (ObvioHealth PTE. LTD.) that functions as the holding structure. The company sells ObvioGo, a unified no-code platform that consolidates the decentralized clinical trial (DCT) software stack — eConsent, ePRO/eCOA, participant engagement, virtual visits, logistics and device management, safety monitoring, recruitment, and central rating — into a single environment, replacing what it states is typically 4–6 separate vendor products. The platform was developed operationally over approximately eight years while running more than 60 real trials before being offered as a licensable product, and is delivered via direct enterprise sales to pharma/biotech sponsors, CROs, medical device and digital therapeutics companies, and consumer health brands, alongside channel partnerships (notably Novotech and sister company SPRIM PRO) and API-first integration with dominant EDC systems including Oracle Clinical One, Medidata, and Veeva.
The business model is enterprise SaaS-style subscription and multi-trial licensing with quote-based pricing; the platform is offered as either an enterprise subscription or a multi-trial license to CROs that deploy ObvioGo as a standardized participant-facing digital layer across their programs. Studies reportedly deploy in approximately 4 weeks (versus 12–16+ weeks for legacy stacks), with disclosed portfolio-level metrics of 91% ePRO compliance, 89% participant retention, 50k+ consented participants, and operations across 40 countries and 6 continents. Revenue is not publicly disclosed; cumulative disclosed equity funding through 2022 totals approximately $61.85M, with an additional undisclosed round in October 2025. Compliance posture spans ISO 27001, HIPAA, GDPR, CCPA, SOC 2 Type 2, and EU-U.S. Data Privacy Framework certification.
Customer evidence spans large pharma (Pfizer, Janssen, Abbott, RedHill Pharma), consumer health multinationals (Haleon, Danone, DSM, FrieslandCampina, Mizkan), medical device and digital therapeutics (Renovia), and CRO channels (Novotech, SPRIM PRO). Named customer engagements include a fully virtual urogynecology trial with 350 patients enrolled in 14 weeks, treatment-resistant depression studies across Australia and New Zealand, and vaccine development with Vaxxas. Distribution is direct enterprise plus CRO-led channel; there is no public or partner-facing API, developer portal, or SDK beyond EDC integrations.
ObvioHealth firmographics
Firmographics- Name
- ObvioHealth
- Legal name
- Obvio Health USA, Inc.
- Website
- https://obviohealth.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ObvioHealth sells ObvioGo, a unified no-code decentralized clinical trial platform that consolidates eConsent, ePRO/eCOA, virtual visits, and device integration into a single system for pharma, biotech, CROs, medical device, and consumer health sponsors globally.
- Ownership category
- akta.pro rank
ObvioHealth industry classification
Industry- Product category
- Decentralized Clinical Trial Software
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
Keywords
Where ObvioHealth is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
ObvioHealth business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Platform Licensing: Multi-trial licensing of ObvioGo platform to CROs and sponsors. The platform is licensed across multiple clinical trials as a standardized participant-facing digital layer, enabling reuse of standardized digital workflows across programs.
- Enterprise Platform Subscription: Enterprise-level platform access with modules for eConsent, ePRO/eCOA, remote and hybrid assessments bundled in a unified system. Studies deploy in approximately 4 weeks on average.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
ObvioHealth product offering
Product offeringCore offering
ObvioHealth provides ObvioGo, an enterprise digital platform for decentralized and hybrid clinical trials that consolidates ePRO, eCOA, eConsent, participant engagement, virtual visits, and device integration into a single no-code environment. The company also operates a COACH clinical oversight team that provides in-app support and monitoring for trial participants. The platform is licensed to pharmaceutical sponsors, biotech firms, CROs, and medical device companies to design, run, and manage remote and hybrid studies.
Product overview
ObvioHealth offers ObvioGo, an enterprise platform for decentralized and hybrid clinical trials that consolidates what typically requires 4-6 separate vendors—ePRO, eConsent, participant engagement, safety monitoring, device integration—into a single no-code environment. The platform comprises multiple integrated modules including Study Designer (no-code protocol development), Study Manager (analytics and dashboards), and the ObvioGo Mobile App (participant-facing interface), alongside functional modules for eConsent and Enrollment, ePRO + eCOA, Data Capture and Monitoring, Virtual Visits and Support, Recruitment and Prescreening, Logistics and Device Management, and Regulatory and Security. The platform is API-first, enabling direct integration with Oracle Clinical One, Medidata, and Veeva. ObvioHealth also provides the COACH Team (Clinical Oversight and Coordination Hub), a virtual site clinical support service. Studies deploy in approximately 4 weeks on average, with 91% ePRO compliance and 89% participant retention reported across their portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- ObvioGo: Enterprise platform combining eConsent, ePRO/eCOA, and remote and hybrid assessments in a single system for decentralized clinical trials.
- COACH (Clinical Oversight and Coordination Hub)
Products and services
- ObvioGo Platform Enterprise platform combining eConsent, ePRO/eCOA, remote and hybrid assessments, virtual visits, and data capture into a unified system for decentralized and hybrid clinical trials. Targets pharmaceutical sponsors, biotechs, CROs, and medical device companies.
- ObvioGo Mobile App Mobile application enabling remote trial participation with eConsent, ePRO/eCOA, image and audio capture, virtual visits, and real-time engagement for clinical trial participants.
- ObvioGo Study Designer No-code, drag-and-drop interface within ObvioGo for building trials from the ground up, simplifying protocol development and adaptation.
- ObvioGo Study Manager Sponsor and investigator-facing tool providing real-time dashboards, data visualization, and analytics capabilities for trial monitoring and outcomes.
- COACH Team (Clinical Oversight and Coordination Hub) Virtual site clinical team that monitors data submission and patient engagement throughout studies, provides live chat support, ensures streamlined processes, and maintains participant safety.
Quantifiable outcome
- 91% ePRO compliance across portfolio
- +6 more outcomes
Companies that use ObvioHealth
Customer profileNamed customers19 records
Segments4 records
Ideal customer profiles4 records
ObvioHealth technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability4 records
Feature9 records
ObvioHealth partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- NovotechcoreObvioHealth announced a strategic multi-trial licensing agreement with Novotech, under which Novotech licenses the ObvioGo platform across multiple clinical trials as a standardized participant-facing digital layer. The agreement enables Novotech teams to reuse standardized digital workflows across programs and reinforces ObvioHealth's role as an enterprise technology partner supporting scalable, sponsor-ready development models.
- Oracle Life SciencescoreObvioGo is now directly integrated with Oracle Clinical One Data Collection, enabling sponsors and CROs to deploy participant-facing trial technologies through a unified clinical trial system. The integration combines ObvioGo's ePRO, eConsent, and eCOA capabilities with Oracle's platform, allowing organizations to limit reliance on multiple third-party solutions while maintaining consistency and scalability across global studies.
- VaxxascoreObvioHealth and Vaxxas entered a three-year partnership to support clinical trials with Vaxxas' needle-free HD-MAP vaccine technology. The collaboration includes using ObvioGo digital trial platform to facilitate vaccine development and testing, with focus on extending access via decentralized trial capabilities.
- SPRIM PROcoreSPRIM PRO and ObvioHealth, sister companies within the SPRIM Group, expanded their collaboration to offer a fully integrated clinical trial solution combining scientific expertise with digital capabilities. The partnership pairs SPRIM PRO's 24 years of clinical experience across 300+ trials with ObvioHealth's ObvioGo platform for decentralized and hybrid trials. The unified offering helps trial sponsors accelerate study startup, improve participant engagement, and deliver regulatory-ready data.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
ObvioHealth competitors and assessment
Company assessmentBroad incumbents
- ICON plc:
- IQVIA: IQVIA is the world's largest CRO and a strategic investor in ObvioHealth. Comparable as a broad incumbent offering DCT capabilities within its full-service CRO portfolio, and as a channel that can route trials to or away from ObvioGo.
Direct peers
- THREAD Research: THREAD provides a decentralized clinical trial platform supporting eCOA, eConsent, virtual visits, and device integrations. Directly comparable as a DCT technology competitor with similar modular offerings to ObvioGo.
- Oracle Health Sciences (Clinical One): Oracle's Clinical One platform is a unified clinical trial system providing EDC, RTSM, and eCOA. Comparable to ObvioHealth as both a direct competitor in DCT and a partner via the Clinical One Data Collection integration announced in 2026.
- Medable: Medable is a leading decentralized clinical trial platform offering eCOA, eConsent, telehealth, and remote monitoring. Directly comparable as a venture-backed DCT software competitor targeting the same pharma/biotech/medical device sponsor base.
- Science 37: Science 37 pioneered the decentralized clinical trial operating model with its patient-facing Metasite technology. Comparable to ObvioHealth as a DCT platform competitor serving large pharma sponsors with remote trial enablement.
- Medidata Solutions: Medidata (Dassault Systèmes) is the dominant eClinical platform with Rave EDC and Patient Cloud ePRO/eConsent. Directly comparable as it offers the same core modules (eCOA, eConsent, remote data capture) that ObvioGo targets, and is the incumbent ObvioHealth explicitly positions against.
- Veeva Systems: Veeva's Vault Clinical platform offers EDC, ePRO, and clinical operations suites widely used in pharma trials. Comparable to ObvioHealth as a Veeva EDC integration partner and as a competing clinical data management platform for enterprise sponsors.
Emerging players
- Curebase: Curebase is an emerging DCT platform combining software with virtual site services for decentralized and hybrid trials. Comparable as a younger competitor in the same decentralized trial software + services category ObvioHealth occupies.
- Castor (CDSS): Castor offers an eClinical platform with EDC, ePRO, and eConsent capabilities focused on flexibility and integration. Comparable as an emerging modular DCT/clinical trial platform competitor, though more research-grade than large-pharma focused.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
ObvioHealth social profiles
Digital presenceObvioHealth compliance and trust
Trust signalCompliance6 records
ObvioHealth financial estimates
Financial estimateRevenue estimate
Valuation estimate
ObvioHealth leadership team
Management profileNumber of profiles
Profiles9 records
ObvioHealth funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ObvioHealth M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ObvioHealth
What does ObvioHealth do?
ObvioHealth provides ObvioGo, an enterprise digital platform for decentralized and hybrid clinical trials that consolidates ePRO, eCOA, eConsent, participant engagement, virtual visits, and device integration into a single no-code environment. The company also operates a COACH clinical oversight team that provides in-app support and monitoring for trial participants. The platform is licensed to pharmaceutical sponsors, biotech firms, CROs, and medical device companies to design, run, and manage remote and hybrid studies.
Is ObvioHealth a public or private company?
ObvioHealth is a private company. It is classified as venture growth investor backed and is currently operating.
When was ObvioHealth founded?
ObvioHealth was founded in 2017. It employs 51 to 100 people.
Where is ObvioHealth based?
ObvioHealth is headquartered in New York, United States, in the North America region.
How does ObvioHealth make money?
Two revenue lines are on record. Platform Licensing is the primary driver. The others are enterprise Platform Subscription.
Who are ObvioHealth's main competitors?
Broad incumbents on record are ICON plc and IQVIA. Direct peers are THREAD Research, Oracle Health Sciences (Clinical One), Medable, Science 37, Medidata Solutions and Veeva Systems. Emerging players are Curebase and Castor (CDSS).
Does ObvioHealth have an API?
No public API is recorded for ObvioHealth.
What industry is ObvioHealth in?
ObvioHealth's product category is Decentralized Clinical Trial Software. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its SIC code is 7372.